| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.84 | 17.26 | -0.05 | 20.07 |
Op profit growth | 22.74 | 5.12 | -20.68 | 41.71 |
EBIT growth | 17.39 | 2.53 | -22.36 | 47.98 |
Net profit growth | 25.01 | -3.47 | -27.49 | 49.21 |
Profitability ratios (%) | ||||
OPM | 19.04 | 15.95 | 17.8 | 22.43 |
EBIT margin | 15.45 | 13.53 | 15.48 | 19.93 |
Net profit margin | 8.86 | 7.29 | 8.85 | 12.21 |
RoCE | 14.29 | 13.41 | 14.28 | 20.93 |
RoNW | 3.69 | 3.45 | 4.16 | 6.82 |
RoA | 2.04 | 1.8 | 2.04 | 3.2 |
Per share ratios (₹) | ||||
EPS | 34.38 | 27.5 | 28.49 | 39.29 |
Dividend per share | 2.5 | 2.5 | 2 | 2 |
Cash EPS | 18.66 | 12.71 | 17.79 | 29.92 |
Book value per share | 250.36 | 215.13 | 182.99 | 159.21 |
Valuation ratios | ||||
P/E | 13.51 | 7.49 | 18.5 | 21.83 |
P/CEPS | 24.89 | 16.2 | 29.63 | 28.66 |
P/B | 1.85 | 0.95 | 2.88 | 5.38 |
EV/EBIDTA | 7.94 | 5.15 | 10.7 | 13.43 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 7.02 | 5.08 |
Tax payout | -30.82 | -30.1 | -28.18 | -24.33 |
Liquidity ratios | ||||
Debtor days | 83.06 | 81.3 | 95.25 | 98.43 |
Inventory days | 73.58 | 71.45 | 83.85 | 74.5 |
Creditor days | -90.57 | -82.83 | -92.71 | -98.99 |
Leverage ratios | ||||
Interest coverage | -4.78 | -3.81 | -4.91 | -7.62 |
Net debt / equity | 0.54 | 0.61 | 0.65 | 0.81 |
Net debt / op. profit | 1.84 | 2.21 | 2.1 | 1.79 |
Cost breakup (₹) | ||||
Material costs | -33.79 | -34.75 | -33.48 | -28.79 |
Employee costs | -21.41 | -21.18 | -20.62 | -18.07 |
Other costs | -25.74 | -28.09 | -28.08 | -30.7 |
Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.
At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.
Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.
Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.
The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.
Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.
ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.
The reshuffle comes after VS Mani, the company's current chief, announced early retirement; he will officially retire as chief on May 26, 2025 after an eight-year career with the company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
